Top

Published in:

27-10-2022 | Insulins | Original Article

Evaluation of the effectiveness of long-acting insulin analogs in patients with type 2 diabetes mellitus

Authors: Tuba Taslamacioglu Duman, Gulali Aktas, Burcin Meryem Atak Tel, Satilmis Bilgin, Gizem Kahveci, Ozge Kurtkulagi

Published in: Journal of Public Health | Issue 12/2023

Abstract

Aim

In this study, we aimed to evaluate the effectiveness of long-acting insulin analogs in the treatment of type 2 diabetes mellitus (T2DM) in our clinic.

Methods

Patients with T2DM who were prescribed long-acting insulin analog therapy in our internal medicine outpatient clinic between November 2017 and December 2019 were included in the study. Patients’ age, gender, duration of diabetes, HbA1c values, insulin doses and injections in previous treatment, and fasting blood glucose levels before the initiation of long-acting insulin analog were recorded. Fasting blood glucose levels after the initiation of long-acting insulin analog therapy, HbA1c values, total insulin doses in the new treatment and the number of injections, and follow-up times were also recorded from the institutional database. Data of the patients during previous treatment and novel treatment were compared.

Results

Forty patients were included in our study. Six patients who did not attend their controls and two patients who were observed to be non-compliant even though they presented to control visit were excluded from the study. The remaining 32 patients were enrolled in the study. The average treatment follow-up period of the patients was 6 (3–8) months. Fasting blood glucose (p = 0.014) and HbA1c (p = 0.004) values were significantly reduced after long-acting insulin analog therapy compared to the values during previous treatment. Similarly, total daily insulin dose was decreased after long-acting insulin analog treatment compared to the insulin dose before long-acting insulin analog treatment (p < 0.001). The decrease in the number of daily insulin injections after long-acting insulin analogs treatment compared to the number of injections before long-acting insulin analog treatment was statistically significant (p < 0.001).

Conclusion

We think that the addition of new long-acting insulin analogs to the treatment in patients with T2DM may be beneficial in achieving the target blood glucose, A1c, and may also be associated with treatment compliance.

Cryer PE (2002) Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 45(7):937–948. https://doi.org/10.1007/s00125-002-0822-9CrossRefPubMed

Franek E, Haluzík M, Varzic SC, Sargin M, Macura S, Zacho J et al (2016) Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with type 2 diabetes. Diabet Med 33:497–505. https://doi.org/10.1111/dme.12982CrossRefPubMed

Haliloglu O, Korkmaz M, Korkmaz P, Sahin S, Durcan E, Siva ZO (2020) Retrospective evaluation of insulin degludec/insulin aspart co-formulation therapy in patients with type 2 diabetes mellitus: a single-center experience. Ann Med Res 27(7):1961–1965. https://doi.org/10.5455/annalsmedres.2020.04.363CrossRef

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38(1):140–149. https://doi.org/10.2337/dc14-2441CrossRefPubMed

Kalra S, Baruah MP (2016) Insulin degludec aspart: One-year real world experience. Indian J Endocrinol Metab 20(3):369–371. https://doi.org/10.4103/2230-8210.177416CrossRefPubMedPubMedCentral

Kaneko S, Chow F, Choi DS, Taneda S, Hirao K, Park Y et al (2015) Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial. Diabetes Res Clin Pract 107(1):139–147. https://doi.org/10.1016/j.diabres.2014.09.026CrossRefPubMed

Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ (2013) Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care 36(11):3411–3417. https://doi.org/10.2337/dc13-0331CrossRefPubMedPubMedCentral

Kumar A, Awata T, Bain SC, Ceriello A, Fulcher GR, Unnikrishnan AG et al (2016) Clinical use of the co-formulation of insulin degludec and insulin aspart. Int J Clin Pract 70(8):657–667. https://doi.org/10.1111/ijcp.12821CrossRefPubMed

Lasserson DS, Glasziou P, Perera R, Holman RR, Farmer AJ (2009) Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia 52(10):1990–2000. https://doi.org/10.1007/s00125-009-1468-7CrossRefPubMed

Liebl A, Davidson J, Mersebach H, Dykiel P, Tack CJ, Heise T (2013) A novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trial. J Diabetes Sci Technol 7(5):1328–1336. https://doi.org/10.1177/193229681300700524CrossRefPubMedPubMedCentral

McMahon GT, Dluhy RG (2007) Intention to treat--initiating insulin and the 4-T study. N Engl J Med 357(17):1759–1761. https://doi.org/10.1056/NEJMe078196CrossRefPubMed

Onishi Y, Ono Y, Rabøl R, Endahl L, Nakamura S (2013) Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial. Diabetes Obes Metab 15(9):826–832. https://doi.org/10.1111/dom.12097CrossRefPubMed

Ozcelik S, Celik M, Vural A, Aydin M, Ozcelik M, Gozu H (2021) Outcomes of transition from premixed and intensive insulin therapies to insulin aspart/degludec co-formulation in type 2 diabetes mellitus: a real-world experience. Arch Med Sci 17(1):1–8. https://doi.org/10.5114/aoms.2020.93264CrossRefPubMed

Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM (2012) Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study. Diabet Med 29(5):682–689. https://doi.org/10.1111/j.1464-5491.2012.03605.xCrossRefPubMedPubMedCentral

Riddle MC, Bolli GB, Ziemen M, Muehlen-Bartmer I, Bizet F, Home PD (2014) New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care 37(10):2755–2762. https://doi.org/10.2337/dc14-0991CrossRefPubMed

Rubin DJ, Rybin D, Doros G, McDonnell ME (2011) Weight-based, insulin dose-related hypoglycemia in hospitalized patients with diabetes. Diabetes Care 34(8):1723–1728. https://doi.org/10.2337/dc10-2434CrossRefPubMedPubMedCentral

Sharma AK, Taneja G, Kumar A, Sahu M, Sharma G, Kumar A et al (2019) Insulin analogs: glimpse on contemporary facts and future prospective. Life Sci 219:90–99. https://doi.org/10.1016/j.lfs.2019.01.011CrossRefPubMed

Working Group (2021a) 6. Glycemic targets: standards of medical care in diabetes-2021. Diabetes Care 44(Suppl 1):S73–s84. https://doi.org/10.2337/dc21-S006CrossRef

Working Group (2021b) 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care 44(Suppl 1):S111–s124. https://doi.org/10.2337/dc21-S009CrossRef

Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rodbard HW, Johansen T et al (2012) Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 35(12):2464–2471. https://doi.org/10.2337/dc12-1205CrossRefPubMedPubMedCentral

Title: Evaluation of the effectiveness of long-acting insulin analogs in patients with type 2 diabetes mellitus
Authors: Tuba Taslamacioglu Duman
Gulali Aktas
Burcin Meryem Atak Tel
Satilmis Bilgin
Gizem Kahveci
Ozge Kurtkulagi
Publication date: 27-10-2022
Publisher: Springer Berlin Heidelberg
Keywords: Insulins
Hypoglycemia
Diabetes
Insulins
Published in: Journal of Public Health / Issue 12/2023
Print ISSN: 2198-1833
Electronic ISSN: 1613-2238
DOI: https://doi.org/10.1007/s10389-022-01769-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Evaluation of the effectiveness of long-acting insulin analogs in patients with type 2 diabetes mellitus

Abstract

Aim

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aim

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2023

The art of forming habits: applying habit theory in changing physical activity behaviour

Establishing and validating a survey for trauma-informed, culturally responsive change across multiple systems

Prevalence and risk factors for female and male adolescents involved in pregnancy and abortion: a population-based cross-sectional study in Taiwan, 2006–2016

Correction to: The art of forming habits: applying habit theory in changing physical activity behaviour

Assessing community readiness for overweight and obesity prevention among Ghanaian immigrants living in Greater Manchester, England

The effect of the health belief model-based educational program on physical activity beliefs and behaviors of university students